caa a22 4500 469094095 CHVBK 20180323133026.0 cr unu---uuuuu 170328e19921201xx s 000 0 eng 10.1007/BF02576253 doi (NATIONALLICENCE)springer-10.1007/BF02576253 Incorporation of 5-fluorouracil into rat liver tumor and normal tissues and the liver nucleotide profile after administration by the hepatic artery during portal venous branch ligation [Elektronische Daten] [B. Jakobsson, G. Roos, I. ElHag, P. Jönsson, U. Stenram] Summary: A therapeutic dose of labelled 5-fluorouracil (5-FU) was infused via the hepatic artery during 30 min with or without ligation of the left portal venous branch in Wistar rats with a secondary liver cancer in the left lateral lobe. After another 60 min, the incorporation of 5-FU into the acid soluble fraction (ASF), ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), was determined in tumor, ligated and unligated liver lobes, small intestine, kidney, and bone marrow. The liver nucleotide profile was examined with isotachophoresis. Portal venous branch ligation (PVBL) caused the following changes, compared with the unligated control group: in the tumor, the incorporation of 5-FU into RNA and DNA decreased and the ratio RNA/acid-soluble fraction labelling decreased. The incorporation increased in intestinal and bone marrow RNA. It was unchanged in liver and kidney. The ratio of tumor to peripheral normal-tissue (small intestine, bone marrow, and kidney) labelling of RNA and DNA decreased. Liver nucleotides (F) UTP, (F)UDP-glucuronic acid, (F)UDP-N-acetylhexosamine, and NAD were lower in the ligated than in the unligated liver lobe. ATP and energy charge did not decrease significantly. In conclusion, PVBL in conjunction with hepatic arterial administration of 5-FU increased systemic drug exposure and possibly decreased hepatic tumor anabolism. It has not been examined how this interferes with the therapeutic effect. Springer-Verlag, 1992 5-Fluorouracil nationallicence Portal venous branch ligation nationallicence Hepatic artery infusion nationallicence Nucleic acids nationallicence Secondary liver tumor nationallicence Jakobsson B. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut Roos G. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut ElHag I. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut Jönsson P. Department of Surgery, Helsingborg Hospital, S-25187, Helsingborg, Sweden aut Stenram U. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut Research in Experimental Medicine Springer-Verlag 192/1(1992-12-01), 13-21 0300-9130 192:1<13 1992 192 433 https://doi.org/10.1007/BF02576253 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02576253 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jakobsson B. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut NATIONALLICENCE 700 1- Roos G. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut NATIONALLICENCE 700 1- ElHag I. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut NATIONALLICENCE 700 1- Jönsson P. Department of Surgery, Helsingborg Hospital, S-25187, Helsingborg, Sweden aut NATIONALLICENCE 700 1- Stenram U. Department of Pathology, University of Lund, S-22185, Lund, Sweden aut NATIONALLICENCE 773 0- Research in Experimental Medicine Springer-Verlag 192/1(1992-12-01), 13-21 0300-9130 192:1<13 1992 192 433 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer